Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.

Autor: Shabil M; University Center for Research and Development, Chandigarh University, Mohali, Punjab, India.; Medical Laboratories Techniques Department, AL-Mustaqbal University, Hillah, Babil, 51001, Iraq., Khatib MN; Division of Evidence Synthesis, Global Consortium of Public Health and Research, Datta Meghe Institute of Higher Education, City: Wardha, India., Ballal S; Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India., Bansal P; Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, 303012, India., Tomar BS; Institute of Pediatric Gastroenterology and Hepatology, NIMS University, Jaipur, India., Ashraf A; Chandigarh Pharmacy College, Chandigarh Group of College, City: Jhanjeri, Mohali, 140307, Punjab, India., Kumar MR; Department of Chemistry, Raghu Engineering College, Visakhapatnam, 531162, Andhra Pradesh, India., Sinha A; School of Applied and Life Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, India., Rawat P; Department of Biotechnology, Graphic Era (Deemed to be University, Dehradun, 248002, India.; Department of Allied Sciences, Graphic Era Hill University Clement Town, City: Dehradun, 248002, India., Gaidhane AM; Global Health Academy, School of Epidemiology and Public Health, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education, City: Wardha, India. abhay.psm@dmiher.edu.in., Sah S; Department of Paediatrics, Hospital and Research Centre, Dr. D. Y. Patil Medical College, Dr. D. Y. Patil Vidyapeeth, Pune, 411018, Maharashtra, India.; Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune, 411018, Maharashtra, India., Daniel AS; Global Health and Infectious Diseases Control Institute, Nasarawa State University, Keffi, Nigeria. afukonyoshidoiku@tsuniversity.edu.ng., Yappalparvi A; School of Pharmaceutical Sciences, 16 Lovely Professional University, Phagwara, India., Bushi G; Center for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College and Hospital, Saveetha University, Chennai, India.
Jazyk: angličtina
Zdroj: BMC endocrine disorders [BMC Endocr Disord] 2024 Nov 18; Vol. 24 (1), pp. 246. Date of Electronic Publication: 2024 Nov 18.
DOI: 10.1186/s12902-024-01775-2
Abstrakt: Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide, with increased prevalence in individuals with chronic liver conditions and type 2 diabetes mellitus (T2DM). Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) have shown promise in diabetes management and may influence liver disease progression. This systematic review and meta-analysis aimed to assess the efficacy of GLP-1 RAs in reducing the risk of HCC in patients with T2DM.
Methods: We conducted a literature search of PubMed, EMBASE, and Web of Science up to August 1, 2024. Studies that evaluated the incidence of HCC in T2DM patients treated with GLP-1 RAs compared to other therapies were included. Meta-analyses were performed using a random-effects model to compute pooled hazard ratios (HRs) and 95% confidence intervals (CIs), and heterogeneity was assessed using the I² statistic. All statistical analyses were performed in R software version 4.3.
Results: Eight studies met the inclusion criteria. The pooled analysis demonstrated that GLP-1 RA treatment was associated with a significant reduction in HCC risk compared to insulin or no GLP-1 RA treatment (pooled HR = 0.41, 95% CI: 0.28 to 0.55), with considerable heterogeneity (I² = 74%). Compared to metformin and DPP-4 inhibitors, GLP-1 RAs did not significantly alter HCC risk (HR = 0.99, 95% CI: 0.79 to 1.27 for metformin; HR = 1.05, 95% CI: 0.80 to 1.39 for DPP-4 inhibitors). However, GLP-1 RAs were associated with a reduced risk compared to sulfonylureas (HR = 0.78, 95% CI: 0.65 to 0.93).
Conclusion: GLP-1 RAs may offer protective benefits against HCC in T2DM patients compared to insulin or no GLP-1 RAs, but not significantly over other antidiabetic medications. This review indicates the need for further randomized controlled trials to clarify the role of GLP-1 RAs in HCC risk mitigation and to explore their mechanistic pathways in liver disease management.
Competing Interests: Declarations Ethical approval Not required. Consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje